Samsung Biologics Co.,Ltd. (207940.KS)
KRW 959000.0
(-2.14%)
KRW 959000.0
(-2.14%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 857.69 Billion KRW | 7.47% |
| 2022 | 798.05 Billion KRW | 102.76% |
| 2021 | 393.58 Billion KRW | 63.33% |
| 2020 | 240.97 Billion KRW | 18.76% |
| 2019 | 202.9 Billion KRW | -9.46% |
| 2018 | 224.1 Billion KRW | 331.11% |
| 2017 | -96.97 Billion KRW | 45.16% |
| 2016 | -176.82 Billion KRW | -109.28% |
| 2015 | 1904.94 Billion KRW | 2086.2% |
| 2014 | -95.9 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 317.99 Billion KRW | 77.29% |
| 2024 Q3 | 264.46 Billion KRW | -16.83% |
| 2024 Q1 | 179.36 Billion KRW | -38.3% |
| 2023 Q1 | 141.75 Billion KRW | -61.68% |
| 2023 Q3 | 240.36 Billion KRW | 30.01% |
| 2023 Q2 | 184.88 Billion KRW | 30.43% |
| 2023 Q4 | 290.68 Billion KRW | 20.93% |
| 2023 FY | 857.69 Billion KRW | 7.47% |
| 2022 Q2 | 152.04 Billion KRW | 3.47% |
| 2022 FY | 798.05 Billion KRW | 102.76% |
| 2022 Q4 | 369.9 Billion KRW | 186.39% |
| 2022 Q3 | 129.16 Billion KRW | -15.05% |
| 2022 Q1 | 146.94 Billion KRW | 85.26% |
| 2021 Q2 | 121.52 Billion KRW | 99.3% |
| 2021 FY | 393.58 Billion KRW | 63.33% |
| 2021 Q4 | 79.31 Billion KRW | -39.81% |
| 2021 Q3 | 131.77 Billion KRW | 8.44% |
| 2021 Q1 | 60.97 Billion KRW | -36.63% |
| 2020 Q4 | 96.22 Billion KRW | 71.58% |
| 2020 Q3 | 56.08 Billion KRW | 7.81% |
| 2020 Q1 | 36.65 Billion KRW | -82.6% |
| 2020 FY | 240.97 Billion KRW | 18.76% |
| 2020 Q2 | 52.01 Billion KRW | 41.92% |
| 2019 Q1 | -38.45 Billion KRW | -112.12% |
| 2019 FY | 202.9 Billion KRW | -9.46% |
| 2019 Q4 | 210.62 Billion KRW | 377.13% |
| 2019 Q3 | 44.14 Billion KRW | 429.15% |
| 2019 Q2 | -13.41 Billion KRW | 65.12% |
| 2018 Q2 | -19.53 Billion KRW | 58.14% |
| 2018 FY | 224.1 Billion KRW | 331.11% |
| 2018 Q4 | 317.28 Billion KRW | 1275.88% |
| 2018 Q3 | -26.98 Billion KRW | -38.16% |
| 2018 Q1 | -46.65 Billion KRW | -361.93% |
| 2017 Q4 | -10.1 Billion KRW | 68.13% |
| 2017 Q1 | -33.07 Billion KRW | 41.96% |
| 2017 FY | -96.97 Billion KRW | 45.16% |
| 2017 Q2 | -22.09 Billion KRW | 33.18% |
| 2017 Q3 | -31.69 Billion KRW | -43.44% |
| 2016 Q3 | -44.1 Billion KRW | 11.85% |
| 2016 Q2 | -50.03 Billion KRW | -94.67% |
| 2016 Q4 | -56.98 Billion KRW | -29.19% |
| 2016 Q1 | -25.7 Billion KRW | 0.0% |
| 2016 FY | -176.82 Billion KRW | -109.28% |
| 2015 FY | 1904.94 Billion KRW | 2086.2% |
| 2014 FY | -95.9 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ORIENT BIO Inc. | 12.87 Billion KRW | -6563.723% |
| Green Cross Holdings Corporation | -54.13 Billion KRW | 1684.318% |
| Green Cross Holdings Corporation | -26.63 Billion KRW | 3320.555% |
| Pharmicell Co., Ltd. | 3.57 Billion KRW | -23871.359% |
| Green Cross Corporation | -26.63 Billion KRW | 3320.555% |
| GeneOne Life Science, Inc. | -77.76 Billion KRW | 1202.884% |
| Celltrion, Inc. | 535.64 Billion KRW | -60.122% |
| SK bioscience Co.,Ltd. | 22.31 Billion KRW | -3743.096% |
| SK Biopharmaceuticals Co., Ltd. | -32.88 Billion KRW | 2708.324% |
| Prestige BioPharma Limited | -32.92 Billion KRW | 2705.283% |